Harmonizing heterogeneous endpoints in COVID-19 trials without loss of information –an essential step to facilitate decision making

Maja von Cube, Marlon Grodd, Martin Wolkewitz, Derek Hazard, Jerome Lambert
doi: https://doi.org/10.1101/2020.03.31.20049007

Article Information

doi 
https://doi.org/10.1101/2020.03.31.20049007
History 
  • April 3, 2020.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

Author Information

  1. Maja von Cube1,2,*,
  2. Marlon Grodd1,2,
  3. Martin Wolkewitz1,2,
  4. Derek Hazard1,2 and
  5. Jerome Lambert1,3
  1. 1Institute of Medical Biometry and Statistics, Faculty of Medicine and Medical Center - University of Freiburg, Germany
  2. 2Freiburg Center for Data Analysis and Modeling- University of Freiburg, Germany
  3. 3University of Paris, Paris, France; ECSTRA Team, Epidemiology and Biostatistics Sorbonne Paris Cité Research Centre UMR 1153, Inserm, Paris, France
  1. ↵*Corresponding author; email: cube{at}imbi.uni-freiburg.de
Back to top
Posted April 03, 2020.
Download PDF

Supplementary Material

Data/Code
Email
Harmonizing heterogeneous endpoints in COVID-19 trials without loss of information –an essential step to facilitate decision making
Maja von Cube, Marlon Grodd, Martin Wolkewitz, Derek Hazard, Jerome Lambert
medRxiv 2020.03.31.20049007; doi: https://doi.org/10.1101/2020.03.31.20049007
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area